Board Meeting

2 July 2026

Agenda

• Welcome and opening

  Verification of quorum and review of the agenda
• 2026 goals progress

  Progress against the business plan; revenue and invoicing versus end-of-year targets (€1.3M revenue, €1.0M invoiced, UK as new market, CE MDR + FDA pre-submission)
• Team

  • Hiring deliberately slowed to preserve cash; only business-critical roles kept open
  • Open vacancies, both necessary: Customer Success and Project Manager
  • Customer Success is the priority: needed to strengthen product adoption. The team is currently a single person and is stretched beyond capacity
• Product and regulatory

  • ENS (Esquema Nacional de Seguridad) High-level certification (categoría Alta) received: unlocks Spanish public-sector procurement at the highest security tier
  • MDR (Class IIb under Rule 11): still pending; news expected before the end of summer
  • FDA: preparing the full documentation for the pre-submission, which we expect to submit before the summer
• Cashflow and funding

  On track with forecasts.

  Grants

  New grant applications since the March board:

  • Fast Track Innobideak (SPRI), aEASI project: submitted 30 April 2026
  • CDTI Misiones 2026 "dIAna", consortium led by Almirall: submitted 12 June 2026

  Awaiting resolution (around €1.9M of non-dilutive aid):

  Grant	Eligible base	Aid requested	Expected resolution
  Red.es RedIA Salud	€1.364.581	€818.748 (60%)	September 2026
  CDTI Misiones 2026 (dIAna)	€998.653 (I+D)	€758.120	Q4 2026
  Fast Track Innobideak	€520.286	€250.000 (SPRI cap)	by 31 October 2026
  Plan 2i Bizkaia	€245.559	€97.008	September 2026

  Loans

  • ICO Crecimiento Exportadores: submitted on 30 June 2026 (file 2026/EXPO/000356), now under analysis by the ICO (resolution expected within 1 to 2 months). Direct ICO loan, 100% online. We requested €322.132, which is 80% of an R&D-only eligible base of €402.665: industrial property, databases and market prospecting were deliberately left out of the base so as not to consume the de minimis headroom that the Plan 2i 2026 grant still needs. Term 8 years (2 of grace + 6 of amortisation); interest Euribor 1Y + 1,75% market margin with a 100 bps reduction (effective around Euribor 1Y + 0,75%); 0,5% opening fee. Eligibility confirmed by the ICO under route "a" (significant direct export exposure). No non-refundable tranche applies, as the project is 100% intangible.
  • A second ICO line (standard ICO, de minimis-subject, around €200K) remains on hold: our €300K / 3-year de minimis ceiling is essentially used up once the current grants, Plan 2i and the ICO Exportadores are counted. It waits for older aids to expire and free headroom (around €37K frees when the 2023 international aid lapses on 14 July 2026, a further €24K in October 2026, with larger room from mid-2027).
  • Elkargi Fondo Innovación: application already submitted and under analysis, requesting €250K. Term 4 years (1 of grace + 3 of amortisation); Euribor 6M + 1,5% (currently around 3,05%); no fees; 100% guaranteed by Elkargi (own SGR product, no external collateral); a market-rate commercial loan, so it does not consume de minimis.
  • Bilateral bank lines (in parallel): Santander has declined our advance lines (líneas de anticipo) at the risk-assessment stage. Despite factors in our favour (working capital, low leverage), they focused on the balance sheet and did not give enough weight to our intangible assets. We are now in conversations with Sabadell and CaixaBank.

  Convertible note (least advanced)

  • Mutua Ventures confirmed (pro-rata)
  • Email sent to the remaining shareholders; no response yet
  • Conversations with new investors not yet started
• Convening a General Shareholders' Meeting

  Proposal to convene a General Shareholders' Meeting (Junta General) as an all-shareholder update on the company, with a live Q&A session.
• Questions, comments, and next steps

Attendees

Board members

Name	Role	Representing
D.ª Sheyla Andina Aguilar Robles	Chair	Legit.Health
D. Alfonso Medela Ayarzaguena	Secretary	Legit.Health
D. Andres Sanchez Hontoria	Member	Mutua Ventures SAU

Guests

Name	Organization
Iker Camara (CFO)	Legit.Health

Observers

Organization	Representative
Telefónica Open Innovation SLU	Carlos Ruisánchez
Legit.Health	Taig Mac Carthy
Legit.Health	Gerardo Fernández
Angels Capital SLU	Celia Viana
Ribera Salud Tecnologías SLU	Manuel Bosch